A group of 27 patients diagnosed with metastatic triple-negative breast cancer (mTNBC) was randomly distributed into two groups and underwent different lines of metronomic treatment (mCHT). The former group (N 14) received first-line mCHT and showed a higher overall survival rate than the second group (N 13), which underwent second-line mCHT. Analysis of one patient still alive from the first group, diagnosed with mTNBC in 2019, showed a complete metabolic response (CMR) after a composite approach implicating first-line mCHT followed by second-line epirubicin and third-line nab-paclitaxel, and was chosen for subsequent molecular characterization. We found altered expression in the cancer stemness-associated gene NOTCH-1 and its corresponding protein. Additionally, we found changes in the expression of oncogenes, such as MYC and AKT, along with their respective proteins. Overall, our data suggest that a first-line treatment with mCHT followed by MTD might be effective by negatively regulating stemness traits usually associated with the emergence of drug resistance.

Ilari, A., Cogliati, V., Sherif, N., Grassilli, E., Ramazzotti, D., Cordani, N., et al. (2024). Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer. BIOMEDICINES, 12(2) [10.3390/biomedicines12020272].

Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer

Ilari, Alice;Sherif, Noorhan;Grassilli, Emanuela;Ramazzotti, Daniele;Cordani, Nicoletta;Cazzaniga, Giorgio;Di Bella, Camillo;Lavitrano, Marialuisa;Cazzaniga, Marina Elena;Cerrito, Maria Grazia
2024

Abstract

A group of 27 patients diagnosed with metastatic triple-negative breast cancer (mTNBC) was randomly distributed into two groups and underwent different lines of metronomic treatment (mCHT). The former group (N 14) received first-line mCHT and showed a higher overall survival rate than the second group (N 13), which underwent second-line mCHT. Analysis of one patient still alive from the first group, diagnosed with mTNBC in 2019, showed a complete metabolic response (CMR) after a composite approach implicating first-line mCHT followed by second-line epirubicin and third-line nab-paclitaxel, and was chosen for subsequent molecular characterization. We found altered expression in the cancer stemness-associated gene NOTCH-1 and its corresponding protein. Additionally, we found changes in the expression of oncogenes, such as MYC and AKT, along with their respective proteins. Overall, our data suggest that a first-line treatment with mCHT followed by MTD might be effective by negatively regulating stemness traits usually associated with the emergence of drug resistance.
Articolo in rivista - Articolo scientifico
AKT; c-MYC; cancer stem cells (CSCs); metastatic triple-negative breast cancer (mTNBC); metronomic therapy (mCHT); NOTCH-1;
English
25-gen-2024
2024
12
2
272
open
Ilari, A., Cogliati, V., Sherif, N., Grassilli, E., Ramazzotti, D., Cordani, N., et al. (2024). Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer. BIOMEDICINES, 12(2) [10.3390/biomedicines12020272].
File in questo prodotto:
File Dimensione Formato  
Zanoletti-2024-Batteries-VoR.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Licenza: Creative Commons
Dimensione 4 MB
Formato Adobe PDF
4 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/457558
Citazioni
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 0
Social impact